Can adjusting guselkumab doses tame tough Crohn's cases?

NCT ID NCT07616687

Recruiting now Disease control Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tests whether increasing the dose of guselkumab can help people with Crohn's disease who don't get better with standard doses. About 210 adults with active Crohn's will receive guselkumab, and after 12 weeks, those who haven't responded will get a higher dose more often. The goal is to see if this approach leads to steroid-free remission and less inflammation at one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: guselkumab (a monoclonal antibody targeting IL-23)
What this could lead to: If successful, this could show that adjusting guselkumab doses helps more Crohn's patients achieve remission without steroids.
What could go wrong: This is a phase 4 study with 210 participants, so results may not apply to all patients. Dose escalation may not improve outcomes and could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD) INTENSIFICATION

Contacts and locations

Locations

Chu Amiens Picardie
RECRUITING

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.